Related Experiment Video
Updated: Nov 20, 2025

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
Published on: June 13, 2025
To Expand the Evidence Base About Harms from Tests and Treatments
Deborah Korenstein1, Russell Harris2, Adam G Elshaug3,4
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. korenstd@mskcc.org.
Understanding healthcare intervention harms is crucial. This study proposes seven patient-relevant harm domains to guide comprehensive harm evaluation in clinical decision-making.
Area of Science:
- Clinical research
- Patient safety
- Health outcomes
Background:
- Limited evidence exists on the full spectrum of patient harms from medical tests and treatments.
- Comprehensive harm assessment is needed for informed clinical decision-making.
Purpose of the Study:
- To develop recommendations for researchers on comprehensively evaluating potential harms of healthcare interventions.
- To enable clinicians and patients to better utilize harm evidence in decision-making.
Main Methods:
- Proposing seven patient-relevant domains of harm: physical impairment, psychological distress, social disruption, disruption in healthcare connection, labeling, financial impact, and treatment burden.
- Highlighting the availability of diverse data and tools for assessing harms across these domains.
- Encouraging evaluation of harms in diverse sub-populations.
Main Results:
- A framework with seven comprehensive domains for evaluating patient harms from healthcare interventions.
- Identification of available data and tools for assessing these harms.
- Emphasis on the importance of considering demographic and clinical characteristics in harm assessment.
Conclusions:
- A structured approach to evaluating patient harms across seven domains can improve the comprehensiveness of research.
- Consideration of diverse populations and available tools can enhance harm assessment.
- Recommendations for regulators, funders, and editors to promote harm reporting are suggested.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
Hazard Ratio
For example, in a clinical trial...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Cancer Survival Analysis
Criteria for Causality: Bradford Hill Criteria - II
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...